As the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...

Nikhil Kamath water business idea: India's rapid growth in water-intensive sectors like agriculture, nuclear energy, pharmaceuticals, and d...

US food safety authorities have expanded a cheese recall due to Listeria contamination, now encompassing all products from Clover Hill Dair...

From a macro perspective, it is clearly a good time to be bullish. But as valuations remain high in parts of the market despite the recent ...

Global drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Com...

On Thursday evening, US President Trump said he would “hit Iran hard tonight”. Then, as the world waited with bated breath, came the announ...

There are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...

India's drug price regulator has increased the ceiling prices of cancer drugs cisplatin and carboplatin by 50% to tackle shortages caused b...

Several states have constituted dedicated multi-member teams to ensure no facility slips through the cracks before a GMP Certificate is iss...

India is increasingly becoming a long-term structural investment destination rather than a short-term strategic bet. Global capital is movi...

Just look at developments in the past 48 hours. The war between Iran and Israel resumed, but within hours Tehran said it had halted all off...

Even in normal times it is futile to try and guess the outcome of most global events. But in the New World Order, it makes no sense at all ...

Inox Clean Energy is acquiring Vena Energy India's 6 GW renewable energy portfolio. This deal significantly expands Inox Clean's operationa...

For the last few earnings seasons, the message has been: “Show me growth, I have the money.” Stocks with better-than-expected earnings saw ...

As global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...

Pharma industry officials say the revised Schedule M regulations could require Rs 10-15 crore per facility in upgrades, while talent shorta...

There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...